Inceptor Bio in-licenses CAR-M Technology from UCSB

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Inceptor Bio executed an in-licensing agreement with the University of California, Santa Barbara for an investigational chimeric antigen receptor macrophage (CAR-M) therapy targeting difficult-to-treat tumors.

Macrophage cells naturally engulf viruses and bacteria through phagocytosis; when combined with a CAR construct to form a CAR-M, they can selectively target and engulf cancer cells and generate an immune response via modulation of the tumor microenvironment. Inceptor’s CAR-M technology plans to optimize the effectiveness of this therapeutic approach. 

The technology was licensed from Denise Montell’s research lab at UCSB. 

YOU MAY BE INTERESTED IN

Veeva Systems formed a ten-year strategic partnership agreement with Merck, that builds on the existing 12-year partnership between the companies. Under the terms of the agreement, Merck will take a Veeva-first approach to new industry-specific software and data, selecting Veeva products when they are fit for purpose to maximize the value of Veeva’s integrated, cloud-based platform and products. 

Login